ZTZ Bio Secures Fourth Global Big Pharma Partnership for Long-Acting Injectable Drug Development
核心洞察
ZTZ Bio (搜索) announced a joint R&D contract with a Europe-based global pharmaceutical company to develop long-acting injections using its proprietary InnoLAMP (搜索) technology platform.
The collaboration involves developing formulations for peptide-based drugs with enhanced bioavailability and reduced injection site reactions, representing the company's fourth major pharma partnership.
ZTZ Bio (搜索)'s pipeline includes advanced clinical programs for Alzheimer's disease (搜索), diabetes (搜索), obesity (搜索), and postoperative pain (搜索), with several candidates having completed Phase 1 trials.
ZTZ Bio (搜索), a South Korean drug development company specializing in long-acting injectable formulations, has secured its fourth global pharmaceutical partnership through a joint R&D agreement with a Europe-based multinational pharmaceutical company. The collaboration focuses on developing next-generation long-acting injections using ZTZ Bio's proprietary InnoLAMP (搜索) technology platform.
Strategic Partnership Details
Under the newly announced agreement, ZTZ Bio (搜索) will apply its core InnoLAMP (搜索) technology to develop formulations for peptide drugs provided by the European partner. The company will derive and provide prototype formulations suitable for preclinical pharmacokinetics (PK) and pharmacodynamic (PD) evaluation, while the partner company will conduct animal testing to assess efficacy.
The financial terms include a down payment exceeding 10% of ZTZ Bio (搜索)'s previous year sales, which totaled approximately 700 million won, indicating a contract value of tens of millions of won. Both the partner company's identity and the complete contract amount remain confidential.
If commercialization proceeds based on positive findings, ZTZ Bio (搜索) will grant exclusive licensing options for the company's background intellectual property rights and improvements, including non-exclusive, global, and permanent sublicensing rights.
Technology Platform Advantages
ZTZ Bio (搜索)'s InnoLAMP (搜索) technology platform offers several differentiated capabilities for long-acting drug delivery. The platform enables mass production scalability, stable incorporation of high-dose drugs into particulates, enhanced bioavailability, and minimized injection site reactions. The technology demonstrates particular strength in peptide and small molecule drug formulations, with drug content exceeding 40%.
"This contract is encouraging in that our technology is recognized by global big pharmas," said Lee Hee-yong, CEO of ZTZ Bio (搜索). "We will accelerate our business expansion based on the fourth global cooperation."
Expanding Partnership Portfolio
This latest agreement represents ZTZ Bio (搜索)'s fourth major pharmaceutical collaboration. The company previously signed joint development contracts with global pharmaceutical companies in 2023, established a Consigned Development and Manufacturing Organization (CDMO) collaboration with a U.S. global company, and secured an additional formulation development contract with Boehringer Ingelheim earlier this year.
The Boehringer Ingelheim partnership has proven particularly productive, with the German pharmaceutical giant signing a follow-up contract following their initial formulation joint development agreement in January. This additional agreement involves Boehringer Ingelheim providing information on new peptide drugs and formulations, with ZTZ Bio (搜索) responsible for developing long-lasting injections using InnoLAMP (搜索) technology.
Clinical Pipeline Progress
ZTZ Bio (搜索) is advancing a diverse pipeline of sustainable formulation candidates across multiple therapeutic areas. The company's lead programs include one-month long-lasting dementia (搜索) treatments GB-5001 and GB-5001A, which have completed Phase 1 clinical trials in Canada and Korea, respectively. For postoperative pain (搜索) management, the company's GB-6002 candidate, designed to provide more than three days of sustained relief, has also completed Phase 1 trials in Korea.
The development pipeline extends to metabolic disorders, with GB-7001 for diabetes (搜索) and obesity (搜索) treatment currently in active development. These programs demonstrate the versatility of the InnoLAMP (搜索) platform across various therapeutic indications including Alzheimer's disease (搜索), diabetes, obesity, and postoperative pain (搜索) management.
Market Position and Future Outlook
The successive partnerships with global pharmaceutical companies have strengthened ZTZ Bio (搜索)'s market position in the long-acting drug delivery sector. The company passed preliminary screening for KOSDAQ listing in June and has initiated the full listing process, reflecting growing investor confidence in its technology platform.
"The successive cooperation with global pharmaceutical companies and entry into the listing process are a result of reflecting the market's confidence in our technology," noted CEO Lee Hee-yong. "While providing better treatment options to patients around the world, we will grow into a leading company in the global long-term sustainable formulation market in the long term."
The company's strategic focus on sustainable drug delivery addresses significant unmet medical needs in chronic disease management, where improved patient compliance through reduced injection frequency can enhance therapeutic outcomes. The InnoLAMP (搜索) platform's demonstrated scalability and effectiveness position ZTZ Bio (搜索) to capitalize on the growing demand for long-acting injectable formulations across multiple therapeutic areas.